Supernus Pharmaceuticals Inc
NASDAQ:SUPN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.77
37.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Supernus Pharmaceuticals Inc
Wall Street
Price Targets
SUPN Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
SUPN
is 40.04 USD
with a low forecast of 36.36 USD and a high forecast of 45.15 USD.
SUPN Last Price Targets
Supernus Pharmaceuticals Inc
The latest public price target was made on Sep 11, 2024 by
David Amsellem
from
Piper Sandler
,
who expects
SUPN
stock to
rise by 1%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
David Amsellem
Piper Sandler
|
36
USD
Upside 1% |
3 months ago
Sep 11, 2024
|
Piper downgrades Supernus to Neutral on slower Qelbree growth
TheFly
|
|
David Amsellem
Piper Sandler
|
41
USD
Upside 15% |
7 months ago
May 24, 2024
|
Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN)
StreetInsider
|
Annabel Samimy
Stifel Nicolaus
|
38
USD
Upside 7% |
8 months ago
Apr 8, 2024
|
Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
StreetInsider
|
Irene Buhalo
Jefferies
|
40
USD
Upside 12% |
8 months ago
Apr 8, 2024
|
Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830'
StreetInsider
|
Price Targets
Operating Income
Forecast
Operating Income Estimate
Supernus Pharmaceuticals Inc
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's operating income is
-4%.
The projected
CAGR
for the next 4 years is
95%.
Net Income
Forecast
Net Income Estimate
Supernus Pharmaceuticals Inc
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's net income is
-26%.
The projected
CAGR
for the next 4 years is
242%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SUPN's stock price target?
Price Target
40.04
USD
According to Wall Street analysts, the average 1-year price target for
SUPN
is 40.04 USD
with a low forecast of 36.36 USD and a high forecast of 45.15 USD.
What is Supernus Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
6%
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's revenue is
19%.
The projected
CAGR
for the next 4 years is
6%.
What is Supernus Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
95%
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's operating income is
-4%.
The projected
CAGR
for the next 4 years is
95%.
What is Supernus Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
242%
For the last 8 years the
compound annual growth rate for
Supernus Pharmaceuticals Inc's net income is
-26%.
The projected
CAGR
for the next 4 years is
242%.
You don't have any saved screeners yet
